Management and Therapy of Early Pregnancy Complications: First and Second Trimesters

13. Thrombophilia and Pregnancy

Paul W. Hendrix Andrea Tinelli2, 3, 4, 5  Antonio Malvasi6, 7   and Michael J. Paidas8, 9  

(1)

Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520-8063, USA

(2)

Department of Obstetrics and Gynecology, Vito Fazzi Hospital, Lecce, Italy

(3)

Laboratory of Human Physiology, The International Translational Medicine and Biomodelling Research Group, Department of Informatics and Applied Mathematics, Moscow Institute of Physics and Technology (State University), Dolgoprudny, Moscow Region, Russia

(4)

Institute of Physics and Technology (State University), Moscow, Russia

(5)

Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Department of Obstetrics & Gynecology, Vito Fazzi Hospital, Lecce, Italy

(6)

Department of Obstetrics and Gynecology, Santa Maria Hospital, G.V.M. Care and Research, Bari, Italy

(7)

International Translational Medicine and Biomodelling Research Group, Department of Applied Mathematics, Moscow Institute of Physics and Technology (State University), Moscow Region, Russia

(8)

Division of Maternal Fetal Medicine, Yale Women and Children’s Center for Blood Disorders and Preeclampsia Advancement, New Haven, CT 06520-8063, USA

(9)

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA

Paul W. Hendrix

Email: paul.hendrix@yale.edu

Andrea Tinelli

Email: andreatinelli@gmail.com

Antonio Malvasi

Email: antoniomalvasi@gmail.com

Michael J. Paidas (Corresponding author)

Email: michael.paidas@yale.edu

13.1 Introduction

Thrombophilias, both hereditary and acquired, are frequently encountered by today’s obstetricians. The complexity of the disorders makes both patient counseling and management challenging. Our knowledge of thrombophilias is expansive and evolving, causing both debate and frequent clinical practice changes over the past few decades. As new genetic risk factors for thrombosis have been discovered, the clinical implications are slowly being determined. The goal of this chapter is to discuss both hereditary and acquired thrombophilias, emphasizing the first and second trimesters of pregnancy. We will examine the evolving literature of each disorder and discuss current recommendations regarding screening and therapy.

13.2 Pregnancy and Hemostasis

Pregnancy is a true test of the human coagulation system. From implantation through the puerperium, the maternal system must carefully balance between hypercoagulability and hemorrhage. Among the earliest challenges is the establishment of the maternal-fetal interface. The invading embryo’s cytotrophoblasts access the maternal decidual vessels to establish early placental circulation. The endovascular trophoblasts invade the maternal spiral arteries, which after morphological conversion, provide the high-flow, low resistance blood supply necessary to support the rapidly growing gestation. Implantation provides a multitude of opportunities for both hemorrhage and thrombosis, either of which could initiate miscarriage or pathological placentation. Many of the poor obstetrical outcomes discussed later in this chapter are theorized products of a compromised maternal-fetal placental interface, including preeclampsia, intrauterine growth restriction, pregnancy loss, and abruption.

Delivery and the puerperium make up another serious challenge to the maternal coagulation system. The rapid transition from the 600 to 700 ml/min blood flow to a term placenta (approximately 80 % of uterine blood flow) to appropriate postpartum bleeding is critical [1].

Though much of the hemostatic burden is carried by myometrial contractions and vasospasm, a substantial amount is left to the maternal coagulation cascade to prevent life-threatening postpartum hemorrhaging. This responsibility leads to an increased risk for thrombotic complications, particularly in the setting of a concurrent clotting disorder. Venous thromboembolism (VTE) complications remain a leading cause of maternal death (Fig. 13.1), accounting for an estimated 9.3 % of maternal deaths in the United States from 2006 to 2010 [2]. Risk factors for maternal venous thromboembolism are presented in Table 13.1 [37].

A339784_1_En_13_Fig1_HTML.jpg

Fig. 13.1

A maternal death for venous thromboembolism (VTE) in pregnancy

Table 13.1

Antepartum and postpartum risk factors for VTE in pregnancy

Antepartum and Postpartum VTE

Odds ratio (95 % CI)

Thrombophilia [3]

51.8 (38.7–69.2)a

Previous VTE [3]

24.8 (17.1–36.0)

Family history of VTE [4]

3.9b

Superficial venous thrombosis [5]

10.0 (1.3–78.1)

BMI >25 kg/m2c [6]

1.8 (1.3–2.4)

Antepartum immobilization [6]

7.7 (3.2–19.0)

BMI >25 kg/m2c and antepartum immobilization [6]

62.3 (11.5–337.6)

Antepartum VTE [6]

Assisted reproduction

4.3 (2.0–9.4)

Smoking

2.1 (1.3–3.4)

Postpartum VTE [6]

Hemorrhage (without surgery)

4.1 (2.3–7.3)

Hemorrhage (with surgery)

12.1 (3.9–36.9)

Infection (vaginal)

20.2 (6.4–63.5)

Infection (cesarean)

6.2 (2.4–26.3)

IUGR

3.8 (1.4–10.2)

Preeclampsia

3.1 (1.8–5.3)

Preeclampsia and IUGR

5.8 (2.1–16.0)

Emergency cesarean delivery

2.7 (1.8–4.1)

Other possible risk factors

Cesarean delivery [3]

2.1 (1.8–2.4)

Cesarean delivery [6]

1.3 (0.7–2.2)

Age [3]

2.1 (2.0–2.3)

Age [6]

0.8 (0.6–1.1)

Parity [5]

1.1 (0.9–1.4)

Parity [6]

1.7 (1.2–2.4)

Adapted from Bourjeily et al. [7]

VTE venous thromboembolism, BMI body mass index. IUGR intrauterine growth restriction, [ ] = reference

aRisk varies by type of thrombophilia

b95 % CI not reported; p< 0.05

cBMI at the time of the first prenatal visit

Pregnancy has multiple physiological changes that make women susceptible to VTE. All three elements of Virchow’s triad (Fig. 13.2) are present, including venous stasis, endothelial injury, and a hypercoagulable state. Hormone changes of pregnancy lead to lower extremity pooling and venous stasis secondary to vasodilation (Fig. 13.3). The uterine compression of the pelvic venous return further augments maternal lower extremity venous stasis (Fig. 13.4). Whether provider recommended or self-prescribed, decreased maternal activity can be an additional contributor to decreased lower extremity venous flow. Endothelial injury and thrombus formation (Figs. 13.513.613.713.8, and 13.9) are present especially at time of delivery. The primary endothelial injury occurs at the uterine placental site, and the risk of VTE is enhanced by cesarean section and operative delivery [8].

A339784_1_En_13_Fig2_HTML.gif

Fig. 13.2

The elements of Virchow’s triad, (a) venous stasis, (b) endothelial damage, and (c) venous thrombus formation; (d) magnification of the thrombus

A339784_1_En_13_Fig3_HTML.jpg

Fig. 13.3

Front section of saphenous vein: (a) incontinence of the venous valves and (b) thrombus formation

A339784_1_En_13_Fig4_HTML.gif

Fig. 13.4

The venous stasis secondary to vasodilation in pregnancy in combination with incontinence valve causes the formation of varicose veins in the legs

A339784_1_En_13_Fig5_HTML.jpg

Fig. 13.5

Endothelial injury

A339784_1_En_13_Fig6_HTML.jpg

Fig. 13.6

Platelet adhesion to damaged endothelium

A339784_1_En_13_Fig7_HTML.gif

Fig. 13.7

Platelet aggregation on the damaged endothelium

A339784_1_En_13_Fig8_HTML.gif

Fig. 13.8

Formation of the platelet plug

A339784_1_En_13_Fig9_HTML.jpg

Fig. 13.9

Thrombus formation

There is also increased risk of VTE with infection, postpartum hemorrhage, and preeclampsia, all of which are associated with endothelial injury [9].

The physiology accounting for the hypercoagulability of pregnancy is complex and generated by a factor combination (Fig. 13.10). Many of the procoagulant factors of the clotting cascade are progressively increased throughout pregnancy including factors II, VII, VIII, and X (Fig. 13.11). Decreases in protein S and resistance to activated protein C also suppress fibrinolysis, further tilting the system toward coagulation [8].

A339784_1_En_13_Fig10_HTML.gif

Fig. 13.10

A factor combination accounting for the hypercoagulability of pregnancy

A339784_1_En_13_Fig11_HTML.gif

Fig. 13.11

Hemostatic, thrombotic, and fibrinolytic pathways. FDP fibrin degradation product. TPA tissue-type plasminogen activator (From Pettker and Lockwood [10])

The addition of a thrombophilia, to a varying extent depending on the specific dysfunction, makes the possibility of VTE substantially higher. The incidence of VTE in pregnancy is approximately 1 per 1500 pregnancies, a prevalence four to six times higher than the rate of women of childbearing ages outside of pregnancy [81113].

Though venous thromboembolism events can happen at anytime throughout pregnancy, it is generally thought 50 % occur before delivery and 50 % occur in the postpartum period. Data regarding specific trimester-related frequency of VTE is contradictory, but it is clear that the increased risk starts with conception, and the most recent data suggest that the thromboembolic risk is exponential as pregnancy proceeds, with the greatest risk in the peri-delivery period [81316].

Seventy to ninety percent of DVTs in pregnancy occur in the left leg (Fig. 13.12). This is explained anatomically due to the right iliac artery crossing the proximal left iliac vein, compressing the vessel. The prompt identification and treatment of thrombosis are important in decreasing mortality or complications of thrombotic disease in pregnancy.

A339784_1_En_13_Fig12_HTML.gif

Fig. 13.12

Seventy to ninety percent of DVTs in pregnancy occur in the left leg

13.3 Hereditary Thrombophilias

The inherited thrombophilias addressed in this chapter are all mutations affecting the coagulation cascade (Fig. 13.13). The multiple enzymes and cofactors required for effective hemostasis make opportunities for genetic variation (Fig. 13.11) [10].

A339784_1_En_13_Fig13_HTML.gif

Fig. 13.13

Schematic description of how it is formed a vascular thrombus; at the bottom right, the factors of the coagulation cascade: (e) erythrocytes, (n) leukocytes, and (f) network of adhesion to endothelium

The most common genetic prothrombotic mutations include heterozygous carriers of factor V Leiden (FVL) and prothrombin gene mutation (PGM) G20210A. Others we will address in this chapter are far less common including deficiencies in protein C, protein S, and antithrombin (Table 13.2) [18].

Table 13.2

The risk of venous thromboembolism in pregnant patient with selected thrombophilias

Condition

Prevalence in European populations

Prevalence in patients with VTE in pregnancy

Risk of VTE without prior history

Risk of VTE with prior history

Factor V Leiden (FVL)

 Heterozygous

5.3 %

44

0.26 %

>10 %

 Homozygous

0.07 %

<1

1.50 %

>10 %

Prothrombin mutation (PGM)

 Heterozygous

2.90 %

17

0.37–0.5 %

>10 %

 Homozygous

0.02 %

<1

2.8

>10 %

Compound FVL/PGM

0.17 %

<1

 

4.70 %

Protein C deficiency

0.2–0.3 %

<14

0.8–1.7 %

 

Protein S deficiency

0.03–0.13 %

12

<1–6.6 %

 

Antithrombin deficiency

0.02–1.1 %

1

11.6 % [17]

11–40 %

Adapted from Han et al. [18]

We will describe the available data regarding both VTE and adverse pregnancy outcomes (Table 13.3).

Table 13.3

Association between hereditary thrombophilias and selected pregnancy complications

 

Preeclampsia

Pregnancy loss

IUGR

Abruption

Recurrent pregnancy loss

Late pregnancy lossb

FVL

1.23 (0.89–1.7) [19]

1.52 (1.06–2.19) [19]

1.0 (0.8–1.25) [19]

1.85 (0.92–3.7) [19]

1.91 (1.01–3.61) [20]a

2.06 (1.1–3.86) [20]

PGM

1.25 (0.79–1.99) [19]

1.13 (0.64–2.01) [19]

1.25 (0.92–1.7) [19]

2.02 (0.81–5.02) [19]

2.70 (1.37–5.34) [20]a

2.66 (1.2–5.53) [20]

Protein C deficiency

21.5 (1.1–414.4) [21]

1.4 (0.9–2.2) [22]

NA

5.93 (0.23–151.58) [20]

1.57 (0.23–10.54) [23]

2.3 (0.6–8.3) [22]

Protein S deficiency

2.83 (0.76–10.57) [20]

1.3 (0.8–2.1) [22]

10.2 (1.1–91) [21]

0.3 (0–70.1) [21]

14.72 (0.99–218.01) [23]

7.39 (1.28–42.83) [23]

Antithrombin deficiency

7.1 (0.4–117.4) [21]

2.1 (1.2–3.6) [22]

NA

4.1 (0.3–49.9) [21]

NA

5.2 (1.5–18.1) [22]

Resources: [1923]

Data are odds ratio (confidence interval 95 %)

IUGR fetal growth restriction, [] = resource

aOnly first trimester losses included

bDefinition of late varied from >20 to >28 weeks of gestation depending on study

Treatment and management of these disorders will be reserved for the end of the chapter.

13.3.1 Factor V Leiden

The inherited thrombophilia most commonly encountered by obstetricians is factor V Leiden (FVL). It is a gene mutation named for the city in which it was first identified in 1994: Leiden, Netherlands [24]. On the procoagulant side of the clotting cascade, factor V is activated by prothrombin to factor Va, which is then a cofactor for the conversion of prothrombin to thrombin. On the anticoagulant side of the equation, factor Va is cleaved by activated protein C and acts as a cofactor for the negative feedback on factor VIII [25]. FVL results from a point mutation in the factor V gene on chromosome 1q23, which codes for an arginine to glutamine substitution at position 506 of the protein. This single amino acid change distorts activated protein C’s cleavage site, impairing its ability cleave factor Va.

FVL is most prevalent in Caucasians of European descent with carrier frequencies estimated at 5–9 % of the population. It is less prevalent in those of Asian and African descent [26]. The rate of homozygosity is approximately of 1 % of those with the gene mutation, and they tend have to have a higher incidence of VTE [2027].

Screening for FVL can be performed by a second-generation APC resistance assay with confirmatory genetic testing for the FVL mutation. However, most providers go directly to genetic testing which is not affected by anticoagulation.

Retrospective data suggests heterozygous carriers of FVL have a five- to tenfold relative risk for VTE during pregnancy, and it is present in 43 % of pregnant women with their first thrombotic event [2831]. It should be pointed out that the overall carrier rate is high and the overall thrombotic incidence is low. The risk of VTE is only 0.25 % in heterozygotes without a family or personal history of thrombosis. For patients with a family or personal history of VTE, the risk could be as high as 10 % [29]. One large multicenter prospective NICHD study looked at 4885 gravid patients without a personal history of thrombotic event. In the 134 FVL carriers found, there was no increase risk of VTE (0 %; 95 % CI, 0–2.7 %) [32].

Contradictory findings confound the association of FVL and spontaneous abortions. A 2003 meta-analysis looking at seven retrospective studies evaluating FVL and recurrent fetal loss before 13 weeks of gestation suggested an association (OR 2.01; 95 % CI, 1.13–3.58) [23]. Similar findings were found in a later systemic review (OR 1.91; 95 % CI 1.01–3.61) [20]. Contrary to this, Roque et al. found FVL to be protective from recurrent fetal losses prior to 10 weeks of gestation in a cohort of women with poor obstetrical outcomes (OR .229; 95 % CI, 0.07–.77) [33]. Another large case-controlled study of 3496 matched women found an association with fetal loss starting after the 10th week of gestation (OR 3.46; 95 % CI, 2.53–4.72) but not from the 3 to 9th week of gestation (OR 1; 95 % CI, 0.4–2.52) [34]. Overall, it appears FVL might be a small risk factor for first trimester loss, and this increased risk is likely limited to after 10 weeks of gestation.

Many studies have found FVL associated with second trimester fetal losses and stillbirth [233537]. One meta-analysis associates FVL with second and third trimester loss with a pooled OR 3.6 (95 % CI, 2.2–5.8). This risk increased with each prior fetal loss and with prior losses at later gestations [38]. Kocher et al. used a prospective case-controlled study of 5000 pregnancies and found a stillbirth association (OR 10.9; 95 % CI, 2.07–56.94) [39].

The protective association of FVL in the first trimester of pregnancy and the association with fetal loss later in pregnancy could be explained by the contrasting environments necessary at the placental interface during different stages of development. The partial pressures of oxygen are low in the mid first trimester: 17 ± 6.9 mmHg at 8–10 weeks when compared to 60.7 ± 8.5 mmHg at 13 weeks [40]. This hypoxia prior to 10 weeks occurs when trophoblasts are invading and plugging the spiral arteries as evidenced by low Doppler blood flow found on ultrasound [41]. If the hypoxic environment persisted or occurred at later gestations, pregnancy loss would be more likely. This provides a plausible mechanism of how an increased clotting tendency would not affect pregnancy viability prior to 10 weeks but be associated with pregnancy loss when a more oxygen-rich milieu is necessary after the first trimester.

While early studies indicated FVL might be a risk factor for intrauterine growth restriction, most studies indicate that an association is not present. Facco et al. evaluated 12 retrospective case-control studies and four retrospective cohort studies in a systemic review [42]. When all studies are included, an association is suggested (OR 1.23; 95 % CI, 1.04–1.44). When the cohort studies were isolated, the pooled OR for the association did not reach statistical significance (OR 1.16; 95 % CI, 0.98–1.38) [42]. Others have found similar findings [194344].

Some available evidence shows an association between the FVL gene mutation and preeclampsia. Lin et al. published a meta-analysis of 12 case-control studies showing an association with both preeclampsia (OR 1.81; 95 % CI, 1.14–2.87) and severe preeclampsia (OR 2.24; 95 % CI, 1.28–3.94) [45]. More recently, a nested case-controlled cohort study of the Danish National Birth Cohort took 519 cases of severe preeclampsia out of 91,661 women and found a positive association (OR 1.94; 95 % CI, 1.27–2.96) [46]. An interesting Italian prospective cohort study showed a higher risk of recurrent preeclampsia in women with FVL (59 %) compared to those without a thrombophilia (25.9 %) [47]. Other studies have failed to find an increased risk of preeclampsia with FVL carriers [323648], including a meta-analysis of nine prospective cohort studies (OR 1.23; 95 % CI 0.89–1.7) [19]. If an association with preeclampsia is present, it is likely not sufficiently significant to alter clinical practice.

Due to the relative infrequency of placental abruption, there are few and conflicting studies evaluating its relationship to FVL. Zdoukopoulos et al. found a positive association in five out of ten retrospective case-control studies. A meta-analysis of those ten studies showed an associative risk (OR 3.42; 95 % CI, 1.42–8.25) [49]. The case–cohort study using the Danish Cohort showed a lower but present association (OR 1.87; 95 % CI 1.25–2.81) among its 378 cases of placental abruption [46]. No association was found in a NICHD multicenter prospective cohort study in which 134 FVL mutation carriers were identified in a cohort of 4885 women. Nested carrier-control analysis found no association with placental abruption [32].

Currently, a consistent association between FVL and abruption has not been shown.

Overall, FVL carriers are at increased risk of VTE in pregnancy. FVL is also associated with fetal losses after 10 weeks and stillbirths. There is not enough evidence to strongly support FVL as a risk factor for preeclampsia, fetal growth restriction, or abruption.

13.3.2 Prothrombin Gene Mutation (PGM)

The second-most prevalent inherited thrombophilia results from a polymorphism in the untranslated 3′ region of the gene coding for prothrombin (factor II). A single guanine (G) to adenine (A) nucleotide point mutation, G20210A, leads to enhanced translation and gene expression. The result is elevated circulating prothrombin plasma levels. The carrier prevalence of PGM is 2–4 % in European Caucasians. Similar to FVL, PGM is much less common in those of Asian and African descent [2627]. Testing is performed by PCR for the specific G20210A mutation.

PGM is a risk factor for VTE, especially during pregnancy. Gerhardt et al. found that 17 % of 119 patients diagnosed with VTE in pregnancy were carriers of the mutation compared to 1.3 % of matched unaffected controls [28]. Other studies have shown a large variation in carrier percentages among patients with their first VTE related to pregnancy, from 31 % out of 42–3.8 % out of 313 [3150]. Like FVL, the overall probability of a thrombosis during pregnancy among PGM carriers without a personal or family history of VTE is as low as 0.37 %. The risk increases to over 10 % for those who have had a prior VTE. The probability appears to be higher for those who are homozygous for PGM mutation, but the available data is sparse [31]. The risk appears much higher for compound heterozygotes for both FVL and PGM, with a 4.6 % probability of a VTE during pregnancy and puerperium even without a prior history [28].

There is conflicting data regarding an association between early fetal loss and PGM carriers (Fig. 13.14). In a meta-analysis of four pooled retrospective studies, PGM carriers had increased risk of recurrent losses before 13 weeks (OR 2.32; 95 % CI, 1.12–4.79) [23]. A similar systemic review of six studies also showed an association with recurrent first trimester loss (OR 2.70; CI 1.37–5.34) [20].

A339784_1_En_13_Fig14_HTML.gif

Fig. 13.14

The second-most prevalent inherited thrombophilia of the gene coding for prothrombin (factor II) is associated with early fetal loss

Both of these pooled studies included multiple small retrospective case-control studies that are prone to bias. Subsequent prospective studies have failed to show an association. In one prospective cohort of 4872 pregnancies tested, 2.8 % were carriers for the PGM G20210A gene, and no association with early fetal loss was found (OR 0.74; 95 % CI 0.30–1.84) [39].

Most available data suggest G20210A gene mutation is not a strong risk factor for stillbirth. Korteweg et al. found in a pooled cohort of 1025 fetal deaths that the rate of PGM was no different than the normal population (2.4 % of mothers) [51]. Kocher’s prospective cohort study of over 4872 women also found no evidence of PGM as risk factor for stillbirth [39]. In secondary analysis of a large prospective multicenter NICHD cohort study of 4167 women enrolled, no association was noted with pregnancy losses across all gestational ages (OR 0.98; 95 % CI 0.49–1.95) [52]. A 2003 systemic review including five case-controlled studies addressing nonrecurrent losses after 20 weeks suggests an association (OR 2.66; 95 % CI 1.28–5.53) [20]. A more recent meta-analysis of four prospective studies failed to show an association with pregnancy loss (OR 1.13; 95 % CI, 0.64–2.01) [19]. Overall, the association between both early pregnancy loss and stillborn is likely modest if present at all.

Studies regarding PGM and fetal growth restriction generally do not support an association. Lykke’s nested case–cohort study of the Danish National Birth Cohort did not show an increased risk of growth restriction in PGM carriers (OR 0.82; 95 % CI 0.46–1.43) [46]. This was similar to prospective data from Silver et al. regarding PGM and for small for gestational age less than 10 % (OR 1.34; 95 % CI; 0.8–2.25) and less than 5 % (OR 1.39; 95 % CI, 0.67–2.89) using sex- and race-specific growth curves [52]. Similar findings were made by others [1936395354].

Studies showing an association between PGM and IUGR have been limited to case-control studies [3755].

Prothrombin gene mutation has not been linked to preeclampsia. In the nested case–cohort evaluation of Danish National Birth Cohort, no association between PGM and severe preeclampsia was found (OR 0.81; 95 % CI, 0.29–2.30) [46].

Rodger et al.’s meta-analysis of prospective studies, including 549 women with PGM, also failed to show an association with preeclampsia (OR 1.25; 95 % CI, 0.79–1.99) [19]. Multiple other studies have shown that PGM is not a risk factor for preeclampsia [3648525657].

The association between PGM and placental abruption is difficult to assess due to the infrequency of abruption. A systemic review including three retrospective case-control studies found a positive association (OR 7.71; 95 % CI 3.01–19.76), but even when pooled, the number of PGM carriers was low (n = 20) [20].

In a prospective cohort of 2034 women, Said et al. found that PGM was an isolated risk factor for abruption (OR 12.15; 95 % CI, 2.45–60.39) [36]. The strongest study available comes from pooled prospective data in a 2010 meta-analysis, which failed to find a significant association (OR 2.02; 95 % CI, 0.81–5.02) [19].

In summary, the prothrombin gene mutation G20210A is a relatively common heritable risk factor for thrombosis especially in pregnancy. VTE risk appears higher in homozygotes and those with compound heterozygotes. There has been contradictory data regarding PGM’s effect on first trimester losses, stillbirth, and abruption. If associations are present, they are likely weak. There is little evidence that preeclampsia and IUGR are associated with PGM.

13.3.3 Protein C Deficiency

Protein C is an anticoagulant responsible for the deactivation of factor Va and factor VIIIa. It is activated by thrombin to activated protein C (APC) which then degrades factors Va and VIIIa, inhibiting clot formation [27].

Protein S, a nonenzymatic cofactor for this action, will be discussed later in this chapter. Protein C’s synthesis (Fig. 13.15a) or functional deficiency is found in 0.2–0.3 % of individuals of European descent. It appears more frequently in those of Asian and African descent [26]. The gene coding for protein C is located on chromosome 2. It is vitamin K dependent and is synthesized by the liver. Two major subtypes of APC deficiencies have been delineated. The more common phenotype, type I, has both reduced protein C levels and activity. Type II phenotypes have quantitatively normal levels of protein C but have compromised functional activity. Laboratory evaluation includes both protein C antigen levels and activity levels. Laboratories typically use activity levels of <50–60 % as abnormal. Testing is unreliable during an acute thrombosis or during anticoagulation therapy.

A339784_1_En_13_Fig15_HTML.gif

Fig. 13.15

Protein C’s synthesis (a); protein C is an anticoagulant and its deficiency is moderately pro-thrombogenic factor (b)

In regard to a thrombotic event risk in pregnancy, protein C deficiency is moderately pro-thrombogenic (Fig. 13.15b). The risk is likely proportional to the deficiency of substrate and/or function. Zotz et al. found the relative risk of a first VTE in pregnancy to be RR 3.0 (95 % CI: 1.4–6.5) if using a <73 % of normal protein C activity cutoff and RR 13.0 (95 % CI, 1.4–123) if using a <50 % cutoff in his case-control study of 173 women with VTE compared to 325 normal controls [29]. A 2006 systemic review of available retrospective case-controlled studies showed a modest risk of VTE (OR 4.76; 95 % CI, 2.15–10.57) in patients with hereditary protein C deficiency [20]. Because both DVT and protein C deficiency are rare, prospective studies regarding their association are unlikely.

Data regarding the association of protein C deficiency and poor obstetrical outcomes is sparse, and the studies available are underpowered. The diverse genetic variants and phenotypes make it difficult to make any conclusion regarding management strategies. Many studies that do include protein C deficiency pool data with protein S and antithrombin deficiency. Preston et al. found the risk of loss in the first or second trimester to be OR 1.4 (95 % CI, 0.9–2.2) compared to a third trimester loss OR 2.3 (95 % CI, 0.6–8.3) [22]. Others have not been able to find associations between recurrent early pregnancy loss and protein C deficiency [58]. In systemic review of retrospective case-controlled studies, Alfirevic et al. found that protein C deficiency was not associated with stillbirth (OR 1; 95 % CI, 0.1–11.1) but was associated with preeclampsia (OR 21.5; 95 % CI, 1.1–414.4). All of the included studies were limited by small study size and large confidence intervals [21]. Our retrospective cohort found an association with preeclampsia (OR 6.85; 95 % CI, 1.09–43.21) and abruption (OR 13.86; 95 % CI, 2.21–86.94) but failed to show associations with the other poor pregnancy outcomes studied [33].

13.3.4 Protein S Deficiency

Protein S is a vitamin K-dependent anticoagulant cofactor in the clotting cascade. It accelerates activated protein C’s disruption of factor Va and factor VIIIa, ultimately suppressing thrombin formation. It is a less common thrombophilia with prevalence of 0.03–0.13 % in the Caucasian European population. The coding gene, PROS1, is located on chromosome 3. There have been over 130 mutations found to cause protein S deficiency with variable expression.

Deficiency of protein S has been divided into three major phenotypes. Type I disease has quantitatively low levels of protein S antigen, both free and total, and decreased function. Type II is characterized by normal free and total protein S levels but compromised functional activity. Type III disease has normal total antigen levels but low of free protein S antigen and activity levels. Protein S activity is variable secondary to fluctuating levels of complement 4B-binding protein, a regulator in the compliment system. Free levels fall throughout pregnancy due to increasing C4b-binding protein. We found in pregnancy free protein S levels substantially lower than nonpregnant values, with free levels of 38.9 ± 10.3 % in the second trimester and 31.2 ± 7.4 % in the third trimester [59]. When indicated, testing for the dysfunction is generally differed until 6-week postpartum to avoid confounding information. Laboratory evaluation is by free protein S antigen levels, which are not reliable in pregnancy, on anticoagulants, or with an active VTE. Free antigen levels below 60 % are considered abnormal, but a diagnosis of hereditary protein S deficiency cannot be made on the basis of protein S activity or free antigen levels when these levels are only determined in pregnancy. Protein S levels must be determined outside of pregnancy and the postpartum period, as well as in the absence of hormonal contraception to confirm the presence of a hereditary protein S deficiency.

Because of the relative infrequency of protein S deficiency, the number of studies regarding its risks during pregnancy is limited. Robertson’s systemic review of available case-controlled studies in 2006 showed an OR 3.19 (95 % CI 1.48–6.88) of VTE and pregnancy [20].

Conard et al.’s evaluation of 44 pregnancies in 17 patients with congenital protein S deficiency showed no thrombosis during pregnancies without anticoagulation but had 5 thrombotic events in the postpartum 17 % (95 % CI 3–31) [60].

The most compelling findings regarding protein S deficiency and pregnancy outcomes have been in regard to late fetal loss, although study sizes are small. A systemic review found a relatively strong association with stillbirth defined as unexplained fetal loss after 20 weeks with no fetal abnormalities (OR 16.2; 95 % CI, 5–52.3) [21]. Similar findings were published by Saade and McLintock, who found an association when looking at fetal losses after 28 weeks (OR 41; 95 % CI, 4.8–359) [61]. Although Alfirevic’s group found associations with both preeclampsia (OR 12.7; 95 % CI, 4–39.7) and IUGR (OR 10.2; 95 % CI, 1.1–91.0) [21], others have failed to find associations with other poor obstetrical outcomes [20].

13.3.5 Antithrombin Deficiency

A less common but more thrombogenic hereditary dysfunction is caused by mutation in the serine protease inhibitor antithrombin (AT) gene. Sometimes referred to as antithrombin III, AT inhibits active thrombin’s conversion of fibrinogen to fibrin. It is also a known inhibitor of factors Xa and IXa, XIa, XIIa, trypsin, plasmin, and kallikrein. Besides its role as anticoagulant, AT has also been found to have anti-inflammatory characteristics [62].

Over 250 mutations have been identified at the AT gene loci which provide a wide spectrum of phenotypes. Type I disease infers a quantitative dysfunction. Type II is the qualitative class of dysfunction, which is further divided into subtypes. Type IIa is characterized by a defect in the reactive site of the protein and is generally more thrombogenic. Type IIb dysfunctions have a defect in the heparin-binding site and are less prone to thrombosis. Type IIc has defects in both binding sites. Type I makes up only 12 % of the total of cases of ATD, but it is much more thrombogenic, accounting for 80 % of symptomatic cases. The prevalence of ATD in Caucasian Europeans is estimated at 0.02–1.15 %. It has been found to be even more common in some Asian populations, with a prevalence of up to 2–5 % [2663].

The laboratory assay of choice is plasma AT activity, which, using heparin, measures how well AT inhibits thrombin or factor Xa. Activity <80 % is considered abnormal, but most patients with hereditary ATD have levels <60 %. Testing can be abnormal secondary to anticoagulation and acute thrombosis and should be delayed until after completing treatment.

The risk of VTE in pregnancy can be high with antithrombin deficiency, though as discussed previously there is large variability among phenotypes. A systemic review reported an OR 4.69 (95 % CI 1.30–16.96) regarding VTE and pregnancy [20]. A more recent systemic review whichincluded 112 pregnancies with AT deficiency without a personal history of VTE, found the incidence risk of VTE to be 11.6 % in each pregnancy (OR 6.09; 95 % CI 1.58–24.43) [17].

Retrospective studies have however estimated the risk for the more thrombogenic type I disease (OR 282; 95 % CI, 31–2532) compared to a much smaller risk with type II disease (OR 28; 95 % CI, 5.5–142) [964]. It is estimated that the lifetime risk of VTE in those with type I disease is 50 % [65]. One case series of 63 untreated women with type I ATD who went through pregnancy without anticoagulation found that 18 % had a thrombotic complication during pregnancy and another 33 % had a thrombotic complication postpartum [60].

Though it is the first inherited thrombophilia identified, the data regarding its association to poor obstetrical outcomes is less robust due to its rarity. Regarding early fetal loss, a retrospective cohort found a modest risk of a fetal loss < 28 weeks in patients with ATD (OR 1.7; 95 % CI, 1–2.8) [22]. A meta-analysis did not find a significant increased risk of recurrent loss before 17 weeks OR 0.88 (95 % CI 0.17–4.48) or nonrecurrent loss at any gestational age 1.54 (95 % CI 0.97–2.45) [23].

Other studies have failed in demonstrating an association with ATD and early pregnancy loss [2033586667].

Studies investigating the relationship between stillbirth and ATD are even more limited due the infrequency of both diagnoses. Prestin’s retrospective cohort study found a significant association (OR 5.2; 95 % CI, 1.5–18.1) [22]. Other attempts to evaluate the risk have been limited by small numbers, but they have not identified a significant association [212368].

We found an increased risk of IUGR (OR 12.93; 95 % CI, 2.72–61.45) and abruption (OR 60.01; 95 % CI, 12.02–300.46) in our retrospective cohort of 491 patients with poor pregnancy outcomes [33]. To the contrary, other small studies have failed to show a significant association [202168].

The relationship between hereditary antithrombin deficiency and preeclampsia requires further refinement. Lariciprete et al. reported an association between hereditary antithrombin deficiency and preeclampsia in a case-controlled study including 12 patients with ATD (RR 0.88 95 %; CI 0.83–0.94) [68]. A systemic review, however, which included only one study by D’Ellia et al., was not able to identify a significant increased risk (OR 3.89; 95 % CI, 0.16–97.19) [20].

The relationship between ATD and preeclampsia is an intriguing subject. A gradual decline in AT activity during the late stage of pregnancy, namely, pregnancy-induced AT deficiency, has been reported in literature, in healthy parturients at term [6269]. Antithrombin activity levels appear to be decreased in pregnancies complicated by preeclampsia. Weiner et al. found mean antithrombin activity to be 60 % ± 15 % in women with preeclampsia compared to 85 % ± 15 % in normal pregnant controls. Using a cutoff ≥ 70 % of AT activity levels provides a negative predictive value of 89 % for preeclampsia. The positive predictive value using a < 70 % AT activity level is 80 % [7071]. Others have found falling AT activity levels in preeclampsia patients that was associated with worsening disease [72].

Antithrombin has a few properties that make it a potential pharmacologic therapy for preeclampsia. AT is a potent anticoagulant and anti-inflammatory agent [73]. Both plasma-derived and recombinant forms of AT are currently available for other indications in pregnancy [74]. Some promising studies have used plasma-derived AT to successfully prolong pregnancy in early onset preeclampsia [7579]. Currently, a large prospective multicenter double-blinded trial is evaluating recombinant AT therapeutic benefits in patients with preterm preeclampsia between 23 and 30 weeks [74].

13.3.6 Methylenetetrahydrofolate Reductase Mutations

Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the folate metabolism pathway. It reduces 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is active in reducing homocysteine to methionine. Defects in the MTHFR gene can lead to elevated levels of homocysteine, which is known to be prothrombotic. The well-studied MTHFR gene is located on chromosome 1p36.4, and two major mutations are common: C677T and A1298C [80].

The C677T allele (cysteine to thymine at nucleotide 677) is relatively common worldwide, with a carrier frequency ranging from 44 % in Italians to 7 % in sub-Saharan Africans. The activity of the enzyme for which it codes is thermolabile, making it less active at temperatures >37 °C. Homozygotes for the C677T allele can have elevated plasma homocysteine levels if they are folate deficient, but normal homocysteine levels are found in those with normal folate levels.

The second commonly discussed mutation is A1298C, which has a less drastic decrease in enzyme function. However, when present compounded with a C677T mutation, it can produce an elevated homocysteine similar to C677T homozygotes when folate deficient [80].

So while MTHFR gene mutations are relatively common, diet and food fortification with folic acid (Fig. 13.16) make hyperhomocysteinemia rare. Hyperhomocysteinemia has been associated with VTE OR 2.5 (95 % CI 1.8–3.5) [81]. MTHFR mutations in the absence of elevated homocysteine levels do not increase VTE risk in isolation regardless of pregnancy status [6482].

A339784_1_En_13_Fig16_HTML.jpg

Fig. 13.16

On the left, folic acid adsorption by diet and food fortification; on the right, synthesis of active forms of folic acid, reducing homocysteinemia and risk of venous thromboembolism (VTE)

A recent large meta-analysis including 11,000 cases and 21,000 controls found those homozygous for MTHFR C677T were not at increased risked for VTE [83].

Though attempts have been made to link MTHFR and hyperhomocysteinemia to adverse pregnancy outcomes, evidence has been contradictory. One meta-analysis found a small association between fetal loss <16 weeks and hyperhomocysteinemia (OR 2.7; 95 % CI, 1.4–5.2) and even smaller with isolated MTHFR (OR 1.4; 95 % CI, 1.0–2.0) [84]. Another group studying homocysteine levels in 5883 woman and their 14,492 pregnancy outcomes found a tendency between elevated levels and stillbirth which did not reach statistical significance (OR 2.03; 95 % CI, 0.98–4.21) [8586]. Other more recent publications have failed to show a relationship between MTHFR and first trimester loss, early fetal loss, or stillbirth [2036].

Though some report the contrary, hyperhomocysteinemia or MTHFR do not appear to be associated with preeclampsia [87], abruption [88], or fetal growth restriction [4289]. If associations do exist, they are likely mild and overcome with folic acid fortification and standard supplementation. Because of the lack of strong evidence between MTFHR and the outcomes discussed above, screening is not recommended. In the often encountered scenario of a patient with a known MTHFR mutation presenting for pregnancy recommendations, folic acid supplementations should be encouraged. No other special care is necessary regarding MTHFR management during pregnancy.

13.4 Acquired Thrombophilia

13.4.1 Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is the most common acquired thrombophilia faced by obstetricians. It has been well associated with both VTE and poor obstetrical outcomes, and it is an important disease for obstetrical providers to understand. APS is an autoimmune disorder in which antibodies are produced targeting endothelial cell membrane phospholipids including cardiolipin, β2-glycoprotein 1, and phosphatidylserine. The subsequent clinical consequences of these antibodies are thrombosis, both venous and arterial, and adverse pregnancy outcomes. These clinical outcomes make up a large part of the diagnosis criteria.

Fifty percent of patients affected by APS have an underlying disease making them at risk for developing the autoantibodies, most commonly systemic lupus erythematosus (SLE). APS was first identified in SLE patients with anticardiolipin antibodies that developed a clotting disorder. Lupus and related rheumatic diseases injure an intact endothelial membrane, exposing anionic phospholipids that bind specialized proteins. This process presents new antigens to an often already compromised immune system. Once the autoantibodies to the endothelial proteins are established, they inhibit endogenous anticoagulants (protein C, annexin V, antithrombin) and promote procoagulants (platelets, tissue factor, and compliment activation). The determination of the mechanism of these modulations is still ongoing [9092].

Diagnosis of APS requires both specific clinical pathology and laboratory criteria as determined by an international consensus group in 2006 (see Table 13.4) [9394]. The first requirement is at least one of the listed clinical outcomes including a thrombotic event or poor obstetrical outcome. The second criterion is the presence of at least one of the listed laboratory abnormalities above the normal threshold, measured twice at least 12 weeks apart.

Table 13.4

Classification criteria for the antiphospholipid syndrome

Antiphospholipid syndrome is present if at least one of the clinical criteria and one of the laboratory criteria below are met

Clinical criteria

 Vascular thrombosis

  One or more episodes of arterial, venous, or small vessel thrombosis in any tissue or organ. Thrombosis must be confirmed by objective validated (unequivocal findings on appropriate imaging studies or histopathology). For histopathological confirmation, thrombosis should be present without evidence of inflammation in the vessel wall

 Morbidity pregnancy

  One or more unexplained death of a morphologically normal fetus at or beyond the 10th week of gestation, with normal fetal morphology documented by ultrasound or by direct examination of the fetus

  One or more premature birth of a morphologically normal neonate before the 34th week of gestation because of eclampsia or severe pre-eclampsia defined according to standard definitions, or recognized features of placental insufficiency

  Three or more unexplained consecutive spontaneous miscarriages before the 10th week of gestation, with maternal anatomical or hormonal abnormalities excluded and paternal and maternal chromosomal caused excluded

Laboratory criteria

 Lupus anticoagulant present in plasma on two or more occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis

 Medium or high titer (>40 lgG or lgM phospholipid unit (1 units is 1 μg of antibody), or >99th centile) of l gG or lgM anticardiolipin antibody in serum or plasma on two or more occasions, at least 12 weeks apart, measured by standardized enzyme-linked immunosorbent assay (ELISA).

 Medium or high titer (>40 lgG or lgG or lgM phospholipid units, or >99th centile) of lgG or lgM anti-β2 glycoprotein I antibody serum or plasma on two or more occasions, at least 12 weeks apart, measured by standardized ELISA, according to recommended procedures

Chart from Cohen et al. [93]

Original source: Miyakis et al. [94]

Antiphospholipid antibodies without the present clinical findings are found in 1–5 % of healthy individuals, many of which are transient [93]. This supports the diagnosis requirement of laboratory abnormality persistence for at least 12 weeks. Many of the studies regarding antiphospholipid antibodies and obstetrical outcomes do not use the strict criteria for APS, often lacking confirmatory lab work at least 12 weeks apart. Other studies were done prior to the establishment of the current diagnosis requirements. It is important to take these limitations into considerations when evaluating the available APS evidence.

APS accounts for 14 % of VTE events during pregnancy. The risk of thrombotic event is varied by the specific laboratory abnormalities. Lupus anticoagulant (LAC) reactivity is a sign of downstream alteration of prothrombin activation and evidence of active disease. Antibody presence alone without LAC abnormality is less likely to cause a thrombotic event. This is well demonstrated in a systemic review of 25 studies (non-obstetric) including 4184 patients and 3151 controls. They found that with lupus anticoagulant (LAC), the venous thrombotic OR was 4.1–16.2 and the arterial thrombosis OR was 8.6–10.8. In the same study, anticardiolipin antibodies (ACA) were more associated with arterial events (OR 1–18) than venous events (OR 1–2.5). The data regarding anti-β2-glycoprotein 1 antibodies was less clear [9596]. Similar findings from a meta-analysis of nonpregnant APS patients with coexisting SLE showed an increased risk of primary VTE OR 6.32 (95 % CI, 3.7–10.8) and recurrent VTE OR 11.6 (95 % CI, 3.7–36.9) in LAC patients compared to ACA carriers primary VTE OR 2.5 (95 % CI, 1.5–4.1) and recurrent VTE OR 3.91 (95 % CI, 1.1–13.4) [97].

The association with APS and first trimester loss is controversial; nonetheless, three unexplained consecutive spontaneous abortions at ≤ 10-week gestation are part of the diagnostic criteria for APS [98]. Most available studies regarding APS and early pregnancy loss use 13 weeks as a cutoff and do not discriminate before and after 10 weeks. As discussed previously, the pathology of losses before 10 weeks and the rest of the third trimester weeks are different. Fifty percent of losses in patients confirmed to have APS are after 10 weeks of gestation [99].

In a study looking at recurrent miscarriage patients with APS, fetal cardiac activity was identified in 86 % of eventual pregnancy losses compared to 43 % in patients without APS (P < 0.01) [100].

An association between fetal loss after the first trimester and APS has been better described [58101102]. In a systemic review of 25 case-control studies, LAC was associated with recurrent pregnancy loss after 24 weeks (OR 7.79; 95 % CI, 2.30–26.45). Similar finding was found with moderate to high ACL IgG (OR 4.68; 95 % CI, 2.96–7.40) [103]. In a recent case-controlled study from the Stillbirth Collaborative Research Network (SCRN), 582 stillbirths diagnosed after 20 weeks were controlled with 1547 live births. They found associations with elevated ACL IgG (OR 3.43; 95 % CI 1.79–6.60) and anti-β2-glycoprotein 1 IgG (OR 3.17; 95 % CI 1.30–7.72). This study was limited by a lack of confirmatory laboratory evaluation 12 weeks apart and inconsistent assessment for lupus anticoagulant [104].

Though more often affecting pregnancies in third trimester, APS has been associated with second trimester placental-mediated obstetrical complications including IUGR and preeclampsia. When APS complicates second trimester pregnancies, the outcomes are often poor [98]. A meta-analysis of 28 studies by Abou-Nassar found LA associated with preeclampsia (OR 2.34; 95 % CI, 1.18–4.64) and IUGR 4.65 (95 % CI 1.29–16.71) in case-controlled studies but not significant with cohort studies [105]. A more recent prospective observational cohort study followed 280 women after a single <10-week embryonic demise with and without positive aPL antibodies and evaluated for their subsequent pregnancy. They found an association between LAC and IUGR (OR 10.27; 95 % CI, 2.37–44.52), ACL IgG and preeclampsia (OR 3.09; 95 % CI 1.13–8.48), and anti-β2-glycoprotein 1 IgG and preeclampsia (OR 4.61 95 % CI 1.53–13.88) [106].

A rare variant form of APS named catastrophic antiphospholipid syndrome (CAPS), also known as Asherson’s syndrome, is an important consideration. It presents as multiple thrombosis (Fig. 13.17a, b) and multiorgan failure secondary to multiple small-vessel occlusions. Though most often associated with infection and trauma, it can be initiated with pregnancy. Of the 255 cases in one international registry, 15 cases were associated with pregnancy. Of those pregnancy related, 50 % occurred during the antepartum, 43 % occurred during the puerperium, and one occurred 2 days after a D and E for an 18-week fetal demise. The mortality among the cases was 46 % [107]. A more recent study reviewed 13 patients with pregnancy-related CAPS in a French APS referral center. Twelve out of 13 patients held the diagnosis of HELLP syndrome prior to CAPS diagnosis at a mean gestational age of 26.6 weeks. Twelve out of 13 of their patients had postpartum CAPS. No maternal deaths were reported. Treatment combinations varied between patients but included heparin, aspirin, steroids, IVIG, cyclophosphamide, plasma exchange, and dialysis [108].

A339784_1_En_13_Fig17a_HTML.jpgA339784_1_En_13_Fig17b_HTML.gif

Fig. 13.17

(a) Hepatic vein thrombosis; (b) retinal thrombosis detected by retinal angiography

Another APS consequence to consider is neonatal antiphospholipid syndrome, a product of transplacental transmission of maternal aPL antibodies affecting the newborn. It is a rare entity which can lead to neonatal thrombosis, thrombocytopenia, livedo reticularis, and pericardial effusions [109].

While neonatal APS is rare, the transplacental transfer of maternal aPL antibodies is found in 5–16 % of APS pregnancies, the clinical significance of which is still being investigated [110111].

In summary, APS is associated with VTE and poor outcomes in pregnancy. Providers should use the current APS criteria when diagnosing patients. Management and treatment of APS will be described in the next section.

13.5 Thrombophilia Evaluation and Management

Obstetrical providers are often faced with prenatal management decisions in women with known or suspected thrombophilias. The management recommendations have been moving targets over the last three decades as more evidence has been published. In this section, we will discuss which patients should be tested for thrombophilias. We will finish the chapter discussing treatment options.

13.5.1 Thrombophilia Evaluation

Recommendations regarding testing for hereditary thrombophilias have been modified multiple times since their discoveries. Stillbirth, abruption, and recurrent pregnancy loss are among the most difficult conditions obstetrical providers must manage. Optimism for new treatments to potentially prevent such tragic outcomes led to the premature adoption of testing and treatment of hereditary thrombophilias with sparse evidence.

As larger prospective studies and meta-analysis have been published, the hereditary thrombophilias have been an overall disappointing therapy target for adverse outcomes. They may assist providers in the evaluation, management, and prevention of VTE associated with pregnancy.

The correct setting for testing for hereditary thrombophilia is a controversial subject. Most agree testing is appropriate for women with a personal history of VTE not associated with a nonrecurrent risk factor (e.g., surgery, immobilization, bone fracture). Testing is also recommended for patients with first-degree relatives diagnosed with high-risk thrombophilia regardless of the patients’ personal VTE history including homozygous FVL and PGM, compound heterozygous FVL and PGM, and antithrombin deficiency. Testing for hereditary thrombophilias is not recommended as part of the evaluation for recurrent pregnancy loss, IUGR, abruption, or preeclampsia.

Thrombophilia evaluation in women experiencing a stillbirth should be limited to those cases where thrombophilia is plausible as an etiology of the stillbirth.

On the other hand, testing for antiphospholipid syndrome is a valuable part of the evaluation in a few obstetrical conditions. The outcomes which make up part of the APS diagnosis criteria are also indications for testing (vascular thrombosis, morphologically normal fetal loss after 10 weeks, three unexplained consecutive pregnancy losses prior to 10 weeks, or a prior delivery prior to 34 weeks for severe preeclampsia or placental insufficiency). See Table 13.4. It is critical that positive testing be repeated after 12 weeks have lapsed to avoid an incorrect diagnoses and unwarranted therapy.

Our screening protocol for inherited and acquired thrombophilia is provided in Table 13.5. The laboratory reliability varies under different clinical scenarios, and some testing should be performed after the anticoagulant course or 6-week postpartum, when using functional assays, not genetic screening tests.

Table 13.5

Screening for thrombophilia

Lupus anticoagulanta

Anticardiolipin IgG, IgM

Anti-β2-glycoprotein I IgG, IgM

Factor V Leiden (PCR)

Prothrombin gene mutation 20210A (PCR)

Protein C activitya, b

Protein S activityc,a,b,d

Antithrombin III activitya,b

aNot reliable on anticoagulation

bNot reliable with active thrombus

cNot reliable in pregnancy

dUse protein S free antigen in pregnancy

13.5.2 Pregnancy Management

Antenatal care for mothers with hereditary and acquired thrombophilia depends on the specific dysfunction and required therapy. Patients should be screened routinely for preeclampsia including BP, urine protein screening, and symptoms. Fetal growth should be routinely monitored by ultrasound in any patient receiving anticoagulation. In APS patients, we start weekly antenatal testing on patients at 36 weeks and deliver at 39 weeks if no complications warrant delivery earlier.

13.6 Anticoagulants in Pregnancy

Common dosing regimens for anticoagulation in pregnancy are reviewed in Table 13.6 [915112113].

Table 13.6

Suggested anticoagulation doses

Prophylactic regimens

First trimester

Second trimester

Third trimester

Unfractionated heparin (UFH)

5000 units twice daily

7500 units–10,000 units twice daily

10,000 units twice daily

Low-molecular-weight heparin (LMWH)

Weight based (initial prenatal weight)

<50 kg

50–90 kg

91–130 kg

131–170 kg

>170 kg

Enoxaparin

20 mg daily

40 mg daily

60 mg dailya

80 mg dailya

0.6 mg/kg dailya

Dalteparin

2500 units daily

5000 units daily

7500 units dailya

10,000 units dailya

75 units/kg dailya

Tinzaparin

3500 units daily

4500 units daily

7000 units daily

9000 units daily

75 units/kg daily

Therapeutic regimens

Initial dose

Adjusted target

Unfractionated heparin (UFH)

10,000 units twice daily

aPTT 1.5–2.5 6 h after injection

Low-molecular-weight heparin (LMWH)

 

Twice daily dosing: antifactor Xa level 0.6–1 units/mL 4–6 h after doseb Once daily dosing: antifactor Xa level >1 units/mL 4–6 h after doseb

Enoxaparin

1 mg/kg twice daily

Dalteparin

200 units/kg dailya

Tinzaparin

175 units/kg daily

Warfarin (postpartum only)

 

Target INR 2.0–3.0

Resources: [915112113]

aMay be given in two divided doses

bIf anti-Xa level monitoring is indicated

Unfractionated heparin (UFH) is an injectable or intravenous anticoagulant commonly used in the obstetrical population. UFH binds to antithrombin, inducing a conformational change that enhances antithrombin’s ability to deactivate coagulation factors IIa and Xa. It is an attractive anticoagulant because it is not teratogenic, it does not cross the placenta, and it is reversible with protamine sulfate. Its side effects include hemorrhage, bone loss, and heparin-induced thrombocytopenia, all of which are rarely seen with prophylactic dosing. If UFH therapy is started, calcium supplementation and periodic platelet monitored should be started.

Low-molecular-weight heparins (LMWH) are a similar group of injectable anticoagulants also commonly used during pregnancy. They are often the preferred therapy over heparin due to ease of use and improved safety profile (Fig. 13.18). LMWH has a longer half-life, requiring less injections, and rarely causes heparin-induced thrombocytopenia. Because of the longer half-life, patients are typically transitioned to UFH at 36 weeks of gestation or earlier if preterm delivery is expected. This therapy conversion is typically performed to decrease the risk of neuraxial anesthesia and bleeding complications around the time of delivery (Fig. 13.19). However, a recent recommendation suggests continuation of LWMH until delivery [114].

A339784_1_En_13_Fig18_HTML.gif

Fig. 13.18

On the top, pregnant patient, pregnant woman, pregnant to submit to scheduled cesarean section at risk for thrombophilia; on the bottom, patient under antithrombotic prophylaxis by low-molecular-weight heparins (LMWH) in puerperium

A339784_1_En_13_Fig19_HTML.gif

Fig. 13.19

A woman receiving regional anesthesia. See text for details

LWMH is not teratogenic and it also does not cross the placenta. Protamine is less effective in reversing LMWH.

Fondaparinux is a synthetic pentasaccharide that binds antithrombin, effectively inhibiting factor Xa. Though its use in pregnancy is limited, there are some small patient series published showing its use in safely pregnancy [115]. It is a promising anticoagulant alternative for patients with heparin hypersensitivity or a history of HIT. Fondaparinux can cross the placenta causing a small but measurable amount antifactor Xa activity in umbilical cord blood samples. More studies are needed to thoroughly evaluate its safety in pregnancy, but its use might be appropriate in carefully selected patients [9116].

Warfarin in pregnancy is a more complicated matter. Warfarin is an oral vitamin K antagonist commonly used for anticoagulation in the nonpregnant population. For patients who conceive on warfarin, conversion to another anticoagulant (typically LMWH) should occur as early as possible once pregnancy is documented, around 5 weeks of gestation, due to its known teratogenic effects. One option is to convert patients from warfarin anticoagulation to LMWH anticoagulation prior to achieving pregnancy. The warfarin-associated embryopathy occurs with early fetal exposure and includes nasal and midface hypoplasia, CNS abnormalities, and skeletal malformations. Warfarin is also usually avoided later in pregnancy because it crosses the placenta, placing the fetus at risk for bleeding complications. The exceptions are in pregnancies complicated by mechanical heart valves, where it is suggested that warfarin is superior in preventing thrombotic complications.

13.7 Hereditary Thrombophilia Treatment

Recommendations regarding anticoagulation in women with hereditary thrombophilias are provided in Table 13.7 [915112113].

Table 13.7

VTE prophylaxis in pregnancy

Thrombophilia classification

History

Antepartum

Postpartum

High-risk thrombophilia

No VTE

P

P

Factor V Leiden (FVL) homozygous

Family VTE or risk factors

P

P

Prothrombin G20210A mutation (PGM) homozygous

One prior VTE

T

T or K

Antithrombin deficiency

Long-term anticoagulation

T

T or K

Compound heterozygote (FVL/PGM)

     

Low-risk thrombophilia

No VTE

Vigilance

Vigilance

FVL heterozygous

Family VTE or risk factors

Vigilance

P

PGM heterozygous

Personal VTE

P

P

Protein C deficiency

Long-term anticoagulation

T

T or K

Protein S deficiency

     

Acquired thrombophilia

No VTE

Vigilance

P

Antiphospholipid antibody syndrome

One prior VTE

T

T or K

 

On long-term anticoagulation

T

T or K

No thrombophilia

One prior VTE associated with nonrecurrent condition

Vigilance

P

One prior VTE in the absence of nonrecurring condition, or on OCPs, or in pregnancy

P

P

Two prior VTE

T

T or K

Resources: [915112113]

P prophylactic dose LMWH or UFH, T therapeutic dose LMWH or UFH, K vit K antagonist

In patients with risk factors requiring prophylactic antepartum anticoagulation, patients are started on subcutaneous LMWH dosing after a positive pregnancy test is confirmed. The patient is converted to subcutaneous UFH if any complications arise suggesting an early delivery or at 36 weeks of gestation. Because the risk of VTE continues into the postpartum period, we restart LMWH after delivery for 6 more weeks of prophylaxis. Patients and providers must have a high suspicion for any sign of DVT or PE, and patients should be evaluated promptly if any concerns arise. In patients on long-term anticoagulation planning for pregnancy, two options are available and management can be individualized. One option is to transition to therapeutic LMWH dosing prior to attempting conception. This approach eliminates the risk of warfarin-related embryopathy but is associated with longer treatment with LMWH. The second option is to maintain the patient on warfarin and transition to LMWH very early in pregnancy, once pregnancy is documented, ideally around 5-week gestation. This must be done understanding the risk of teratogenicity from 6 to 12 weeks of gestation and the implications of missing the conversion window. LMWH can be transitioned to UFH if early delivery becomes likely or at 36 weeks of gestation. Anticoagulation postpartum can be with LMWH or warfarin depending on patient preference. LMWH, UFH, and Coumadin are all compatible with breast-feeding [9]. Due to the highly thrombogenic nature of hereditary antithrombin deficiency, antithrombin replacement therapy is recommended to prevent thromboembolism in high-risk settings of delivery and surgery during pregnancy [117119].

13.8 Antiphospholipid Antibody Syndrome Treatment

In patients with APS, treatment during pregnancy depends on which clinical criteria determined their diagnosis. For those with a history of VTE on lifelong anticoagulation, transitioning to therapeutic LMWH dosing prior to conception is appropriate. They can be transitioned back to warfarin postpartum. If the patient has a personal history of a VTE but is not on long-term anticoagulation, therapeutic dosing of LMWH should be started when pregnancy is diagnosed. If they also have APS-defining pregnancy morbidity, low-dose aspirin should be added in the antepartum.

The optimal treatment of APS patients diagnosed by obstetrical clinical criteria and no VTE history has not yet been determined. Most agree that prophylaxis with LMWH during the pregnancy and 6-week postpartum and clinical surveillance are both appropriate options. For those with a history of a fetal loss, low-dose aspirin in addition to prophylactic dosing LMWH has been found to decrease the risk of reoccurrence [99]. Low-dose aspirin alone or with LMWH can be used for patients that meet APS criteria with a history of a preterm delivery before 34 weeks due to preeclampsia, eclampsia, or placental insufficiency without a VTE history. There is no current evidence regarding isolated positive APS laboratory values in the absence of clinical criteria, though experts suggest low-dose aspirin would be a reasonable prophylaxis in the setting of SLE [93].

The management of pregnancy in rare cases of refractory adverse pregnancy outcomes secondary to APS can be particularly challenging. There are reports of successful use of hydroxychloroquine and corticosteroids in addition to the standard therapies for these rare scenarios, but more studies are needed to prove their efficacy [120].

References

1.

Wang Y, Zhao S (2010) Placental blood circulation. In: Vascular biology of the placenta. Morgan and Claypool Life Sciences, San Rafael

2.

Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM (2015) Pregnancy-related mortality in the United States, 2006–2010. Obstet Gynecol 125(1):5–12PubMed

3.

James AH, Jamison MG, Brancazio LR, Myers ER (2006) Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 194(5):1311–1315PubMed

4.

McColl M, Ramsay J, Tait R, Walker I, McCall F, Connie J, Carty M, Greer I (1997) Risk factors for pregnancy associated venous thromboembolism. Thrombi Headmost 78(4):1183–1188

5.

Danilenko-Dixon DR, Heit JA, Silverstein MD, Yawn BP, Petterson TM, Lohse CM, Melton LJ (2001) Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 184(2):104–110PubMed

6.

Jacobsen A, Skjeldestad F, Sandset P (2008) Ante-and postnatal risk factors of venous thrombosis: a hospital-based case–control study. J Thromb Haemost 6(6):905–912PubMed

7.

Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M (2010) Pulmonary embolism in pregnancy. Lancet 375(9713):500–512PubMed

8.

Marik PE, Plante LA (2008) Venous thromboembolic disease and pregnancy. N Engl J Med 359(19):2025–2033PubMed

9.

Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians evidence-based Clinical Practice Guidelines. Chest J 141(2_Suppl):e691S–e736S

10.

Pettker CM, Lockwood CJ (2012) Thromboembolic disorders. In: Gabbe SG, Niebyl JR, Galan HL (eds) Obstetrics: normal and problem pregnancies. Elsevier Health Sciences, Philadelphia

11.

Cushman M (2007) Epidemiology and risk factors for venous thrombosis. Semin Hematol 44:62–69

12.

Sultan AA, West J, Tata LJ, Fleming KM, Nelson‐Piercy C, Grainge MJ (2012) Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 156(3):366–373PubMed

13.

Virkus RA, Løkkegaard ECL, Bergholt T, Mogensen U, Langhoff-Roos J, Lidegaard Ø (2011) Venous thromboembolism in pregnant and puerperal women in Denmark 1995–2005. Thromb Haemost 106(2):304–309PubMed

14.

Jackson E, Curtis KM, Gaffield ME (2011) Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 117(3):691–703PubMed

15.

James A (2011) Practice Bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 118(3):718–729PubMed

16.

Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M (1999) Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 94(5 Pt 1):730–734PubMed

17.

Rhéaume M, Weber F, Durand M, Mahone M (2016) Pregnancy-related venous thromboembolism risk in asymptomatic women with antithrombin deficiency: A systematic review. Obstetrics & Gynecology 127(4):649–656

18.

Han CS, Paidas MJ, Lockwood CJ (2010) Clotting disorders. In: James DK, Steer PJ, Weiner CP, Gonik B (eds) High risk pregnancy: management options-expert consult. Elsevier Saunders, St. Louis

19.

Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA (2010) The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 7(6):728

20.

Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe G, Walker ID, Greaves M, Brenkel I, Regan L (2006) Thrombophilia in pregnancy: a systematic review. Br J Haematol 132(2):171–196PubMed

21.

Alfirevic Z, Roberts D, Martlew V (2002) How strong is the association between maternal thrombophilia and adverse pregnancy outcome?: a systematic review. Eur J Obstet Gynecol Reprod Biol 101(1):6–14PubMed

22.

Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ (1996) Increased fetal loss in women with heritable thrombophilia. Lancet 348(9032):913–916PubMed

23.

Rey E, Kahn SR, David M, Shrier I (2003) Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361(9361):901–908. doi:10.1016/S0140-6736(03)12771-7PubMed

24.

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67PubMed

25.

Siegert G, Kostka H, Kuhlisch E, Schwarz T, Schellong S, Jaross W (2001) Investigation of genotype-dependent differences in factor V activity as well as response to activated protein C by application of different methods. Blood Coagul Fibrinolysis 12(8):683–690PubMed

26.

Margaglione M, Grandone E (2011) Population genetics of venous thromboembolism. A narrative review. Thromb Haemost 105(2):221–231PubMed

27.

Franco RF, Reitsma PH (2001) Genetic risk factors of venous thrombosis. Hum Genet 109(4):369–384PubMed

28.

Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB (2000) Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 342(6):374–380. doi:10.1056/NEJM200002103420602PubMed

29.

Zotz RB, Gerhardt A, Scharf RE (2003) Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 16(2):243–259PubMed

30.

Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM (2002) Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 87(5):791–795PubMed

31.

Jacobsen A, Dahm A, Bergrem A, Jacobsen E, Sandset P (2010) Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost 8(11):2443–2449PubMed

32.

Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G Jr, Wenstrom K, Samuels P, Cotroneo MA, Moawad A (2012) The relationship of the factor V leiden mutation and pregnancy outcomes for mother and fetus. Am J Perinatol 29(3):225PubMed

33.

Roqué H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ (2004) Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 91(2):290–295PubMed

34.

Lissalde‐Lavigne G, Fabbro‐Peray P, Cochery‐Nouvellon E, Mercier E, Ripart‐Neveu S, Balducchi J, Daures J, Perneger T, Quere I, Dauzat M (2005) In focus: factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case–control ‘NOHA first’ study. J Thromb Haemost 3(10):2178–2184PubMed

35.

Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM (2000) Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 343(14):1015–1018PubMed

36.

Said JM, Higgins JR, Moses EK, Walker SP, Borg AJ, Monagle PT, Brennecke SP (2010) Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 115(1):5–13. doi:10.1097/AOG.0b013e3181c68907PubMed

37.

Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB (1999) Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340(1):9–13PubMed

38.

Dudding TE, Attia J (2004) The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 91(4):700–711PubMed

39.

Kocher O, Cirovic C, Malynn E, Rowland CM, Bare LA, Young BA, Henslee JG, Laffler TG, Huff JB, Kruskall MS (2007) Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay a controlled study of 5,000 patients. Am J Clin Pathol 127(1):68–75PubMed

40.

Rodesch F, Simon P, Donner C, Jauniaux E (1992) Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 80(2):283–285PubMed

41.

Jaffe R (1993) Investigation of abnormal first-trimester gestations by color Doppler imaging. J Clin Ultrasound 21(8):521–526PubMed

42.

Facco F, You W, Grobman W (2009) Genetic thrombophilias and intrauterine growth restriction: a meta-analysis. Obstet Gynecol 113(6):1206–1216. doi:10.1097/AOG.0b013e3181a6e96aPubMed

43.

Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, Ring S, Attia J, Scott R (2008) Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 6(11):1868–1875

44.

Howley HE, Walker M, Rodger MA (2005) A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 192(3):694–708PubMed

45.

Lin J, August P (2005) Genetic thrombophilias and preeclampsia: a meta-analysis. Obst Gynecol 105(1):182–192

46.

Lykke J, Bare L, Olsen J, Lagier R, Arellano A, Tong C, Paidas M, Langhoff-Roos J (2012) Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost 10(7):1320–1325PubMed

47.

Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, Zatti S, Benedetto C (2009) Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 200(1):e41–e46, e45

48.

Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J, Goulet L, Lydon J, Seguin L, Dassa C (2009) Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol 200(2):e151–e159

49.

Zdoukopoulos N, Zintzaras E (2008) Genetic risk factors for placental abruption: a HuGE review and meta-analysis. Epidemiology 19(2):309–323PubMed

50.

Grandone E, Margaglione M, Colaizzo D, D’Andrea G, Cappucci G, Brancaccio V, Di Minno G (1998) Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 179(5):1324–1328PubMed

51.

Korteweg FJ, Erwich JJH, Timmer A, van der Meer J, Ravisé JM, Veeger NJ, Holm JP (2012) Evaluation of 1025 fetal deaths: proposed diagnostic workup. Am J Obstet Gynecol 206(1):e51–e53, e12

52.

Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K, Samuels P, Caritis SN, Sorokin Y, Miodovnik M (2010) Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 115(1):14PubMedPubMedCentral

53.

Franchi F, Cetin I, Todros T, Antonazzo P, de Santis MN, Cardaropoli S, Bucciarelli P, Biguzzi E (2004) Intrauterine growth restriction and genetic predisposition to thrombophilia. Haematologica 89(4):444–449PubMed

54.

Verspyck E, Borg J, Le Cam-Duchez V, Goffinet F, Degre S, Fournet P, Marpeau L (2004) Thrombophilia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 113(1):36–40PubMed

55.

Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, Di Minno G (2001) Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 86(4):428–431PubMed

56.

Morrison E, Miedzybrodzka Z, Campbell D, Haites N, Wilson B, Watson M, Greaves M, Vickers M (2002) Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 87(5):779–785PubMed

57.

Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM (2001) Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 185(1):153–157PubMed

58.

Krabbendam I, Franx A, Bots ML, Fijnheer R, Bruinse HW (2005) Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 118(2):143–153PubMed

59.

Paidas M, Ku DH, Lee MJ, Manish S, Thurston A, Lockwood C, Arkel Y (2005) Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 3(3):497–501PubMed

60.

Conard J, Horellou M, Van Dreden P, Lecompte T, Samama M (1990) Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 63(2):319–320PubMed

61.

Saade GR, McLintock C (2002) Inherited thrombophilia and stillbirth. Semin Perinatol 26:51–69

62.

Ornaghi S, Mueller M, Barnea ER, Paidas MJ (2015) Thrombosis during pregnancy: Risks, prevention, and treatment for mother and fetus—harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of thrombosis. Birth Defects Res C Embryo Today Rev 105(3):209–225

63.

Patnaik M, Moll S (2008) Inherited antithrombin deficiency: a review. Haemophilia 14(6):1229–1239PubMed

64.

McColl M, Ellison J, Reid F, Tait R, Walker I, Greer I (2000) Prothrombin 20210 G → A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG Int J Obstet Gynaecol 107(4):565–569

65.

Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, Hamersley SL, Hyers TM, Katz V, Kuhlmann R (2007) Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 197(5):e451–e457, e421

66.

Folkeringa N, Brouwer JLP, Korteweg FJ, Veeger NJ, Erwich JJH, Holm JP, Van Der Meer J (2007) Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 136(4):656–661PubMed

67.

Jaslow CR, Carney JL, Kutteh WH (2010) Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 93(4):1234–1243PubMed

68.

Larciprete G, Gioia S, Angelucci PA, Brosio F, Barbati G, Angelucci GP, Frigo MG, Baiocco F, Romanini ME, Arduini D, Cirese E (2007) Single inherited thrombophilias and adverse pregnancy outcomes. J Obstet Gynaecol Res 33(4):423–430. doi:10.1111/j.1447-0756.2007.00550.xPubMed

69.

James AH, Rhee E, Thames B, Philipp CS (2014) Characterization of antithrombin levels in pregnancy. Thromb Res 134(3):648–651PubMed

70.

Weiner CP, Brandt J (1980) Plasma antithrombin III activity in normal pregnancy. Obstet Gynecol 56(5):601–603PubMed

71.

Weiner CP, Kwaan HC, Xu C, Paul M, Burmeister L, Hauck W (1985) Antithrombin III activity in women with hypertension during pregnancy. Obstet Gynecol 65(3):301–306PubMed

72.

Marietta M, Simoni L, Pedrazzi P, Facchini L, D’AMICO R, Facchinetti F (2009) Antithrombin plasma levels decrease is associated with preeclampsia worsening. Int J Lab Hematol 31(2):227–232PubMed

73.

Maclean PS, Tait RC (2007) Hereditary and acquired antithrombin deficiency. Drugs 67(10):1429–1440PubMed

74.

Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S (2013) Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomized evaluation of the safety and efficacy of recombinant Antithrombin in very preterm preeclampsia (PRESERVE-1). Am J Reprod Immunol 69(6):539–544PubMed

75.

Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, Maki M (2003) Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers, New York, pp 645–652

76.

Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, Sagara Y, Kajiwara Y, Urata M (2000) Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thromb Haemost 84(4):583–590PubMed

77.

Terao T, Kobayashi T, Imai N, Oda H, Karasawa T (1989) Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT III concentrate. Asia Oceania J Obstet Gynaecol 15(1):25–32PubMed

78.

Nakabayashi M, Asami M, Nakatani A (1998) Efficacy of antithrombin replacement therapy in severe early-onset preeclampsia. In: Seminars in thrombosis and hemostasis. Thieme, New York, pp 463–466

79.

Paternoster DM, Fantinato S, Manganelli F, Milani M, Nicolini U, Girolami A (2004) Efficacy of AT in pre-eclampsia: a case-control prospective trial. Thromb Haemost 91(2):283–289PubMed

80.

Botto LD, Yang Q (2000) 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151(9):862–877PubMed

81.

Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM (1998) Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80:874–877

82.

Domagala T, Adamek L, Nizankowska E, Sanak M, Szczeklik A (2002) Mutations C677T and A1298C of the 5, 10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 13(5):423–431PubMed

83.

Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, Rossi E, Folsom AR, Almawi WY, Scarabin PY (2013) Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 28(8):621–647PubMedPubMedCentral

84.

Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK (2000) Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 74(6):1196–1199PubMed

85.

Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen ALB, Ueland PM (2000) Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 71(4):962–968PubMed

86.

Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE (2004) Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 117(1):26–31PubMed

87.

Also-Rallo E, Lopez-Quesada E, Urreizti R, Vilaseca MA, Lailla JM, Balcells S, Grinberg D (2005) Polymorphisms of genes involved in homocysteine metabolism in preeclampsia and in uncomplicated pregnancies. Eur J Obstet Gynecol Reprod Biol 120(1):45–52PubMed

88.

Ananth CV, Peltier MR, De Marco C, Elsasser DA, Getahun D, Rozen R, Smulian JC, Investigators NJPAS (2007) Associations between 2 polymorphisms in the methylenetetrahydrofolate reductase gene and placental abruption. Am J Obstet Gynecol 197(4):e381–e385, e387

89.

Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, Gauthier R, Feoli-Fonseca JC (2002) Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 347(1):19–25. doi:10.1056/NEJM200207043470105PubMed

90.

Girardi G, Redecha P, Salmon JE (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10(11):1222–1226. doi:10.1038/nm1121PubMed

91.

Field SL, Brighton TA, McNeil HP, Chesterman CN (1999) Recent insights into antiphospholipid antibody-mediated thrombosis. Best Pract Res Clin Haematol 12(3):407–422. doi:http://dx.doi.org/10.1053/beha.1999.0033

92.

Forastiero R, Martinuzzo M (2008) Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 17(10):872–877PubMed

93.

Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM (2010) Diagnosis and management of the antiphospholipid syndrome. BMJ 340(7756):1125–1132

94.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, DEG PG, Derksen RH, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306. doi:10.1111/j.1538-7836.2006.01753PubMed

95.

Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5):1827–1832PubMed

96.

Galli M, Luciani D, Bertolini G, Barbui T (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102(8):2717–2723. doi:10.1182/blood-2002-11-3334PubMed

97.

Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G (1997) Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus–a meta-analysis. Lupus 6(5):467–473PubMed

98.

de Jesus GR, Agmon-Levin N, Andrade CA, Andreoli L, Chighizola CB, Flint Porter T, Salmon J, Silver RM, Tincani A, Ware Branch D (2014) 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 13(8):795–813. doi:http://dx.doi.org/10.1016/j.autrev.2014.02.003

99.

Branch DW (1990) Antiphospholipid antibodies and pregnancy: maternal implications. Semin Perinatol 14(2):139–146PubMed

100.

Rai RS, Clifford K, Cohen H, Regan L (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 10(12):3301–3304PubMed

101.

Gris J-C, Quéré I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland M-L, Hoffet M, Berlan J, Daurès J-P, Marès P (1999) Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent, Th Nîmes Obstetricians and Haematologists Study (NOHA). Thromb Haemost 81(6):891–899PubMed

102.

Rai R, Regan L (2006) Recurrent miscarriage. Lancet 368(9535):601–611PubMed

103.

Opatrny L, David M, Kahn SR, Shrier I, Rey E (2006) Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 33(11):2214–2221PubMed

104.

Silver RM, Parker CB, Reddy UM, Goldenberg R, Coustan D, Dudley DJ, Saade GR, Stoll B, Koch MA, Conway D, Bukowski R, Rowland Hogue CJ, Pinar H, Moore J, Willinger M, Branch DW (2013) Antiphospholipid antibodies in stillbirth. Obstet Gynecol 122(3):641–657. doi:10.1097/AOG.0b013e3182a1060ePubMed

105.

Abou-Nassar K, Carrier M, Ramsay T, Rodger MA (2011) The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 128(1):77–85. doi:http://dx.doi.org/10.1016/j.thromres.2011.02.006

106.

Chauleur C, Galanaud JP, Alonso S, Cochery-Nouvellon E, Balducchi JP, MarÈS P, Fabbro-Peray P, Gris JC (2010) Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 8(4):699–706. doi:10.1111/j.1538-7836.2010.03747.xPubMed

107.

Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP, Andrade DC, Borba EF, Makatsaria A, Bucciarelli S (2007) Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 66(6):740–746PubMedPubMedCentral

108.

Hanouna G, Morel N, Josselin L, Vauthier-Brouzes D, Saadoun D, Kettaneh A, Levesque K, Le Guern V, Goffinet F, Carbonne B (2013) Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology 52(9):1635–1641PubMed

109.

Soares Rolim AM, Castro M, Santiago MB (2006) Neonatal antiphospholipid syndrome. Lupus 15(5):301–303PubMed

110.

Mekinian A, Lachassinne E, Nicaise-Roland P, Carbillon L, Motta M, Vicaut E, Boinot C, Avcin T, Letoumelin P, De Carolis S (2012) European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 72(2):217–222, annrheumdis-2011-201167PubMedPubMedCentral

111.

Magalhães CS, de Souza Rugolo LMS, Trindade CEP (2014) Neonatal antiphospholipid syndrome. Neo Reviews 15(5):e169–e176

112.

Green-top Guideline No. 37a — reducing the risk of thrombosis and embolism during pregnancy and the puerperium (2015) Royal College of Obstetricians and Gynaecologists, London. (https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf)

113.

Green-top Guideline No. 37b — Thromboembolic disease in pregnancy and the P\puerperium: acute management (2015) (https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf)

114.

Solomon CG, Greer IA (2015) Pregnancy complicated by venous thrombosis. N Engl J Med 373(6):540–547

115.

Knol HM, Schultinge L, Erwich JJ, Meijer K (2010) Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost 8(8):1876–1879PubMed

116.

De Carolis S, di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino D, Lanzone A, De Stefano V (2015) Fondaparinux in pregnancy: could it be a safe option? A review of the literature. Thromb Res 135(6):1049–1051PubMed

117.

Paidas MJ, Forsyth C, Quéré I, Rodger M, Frieling JT, Tait RC, Group RHAS (2014) Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagul Fibrinolysis 25(5):444–450PubMed

118.

Paidas MJ, Triche EW, James AH, DeSancho M, Robinson C, Lazarchick J, Ornaghi S, Frieling J (2016) Recombinant human antithrombin in pregnant patients with hereditary antithrombin deficiency: integrated analysis of clinical data. Am J Perinatol 33(4):343–349

119.

James AH, Konkle BA, Bauer KA (2013) Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Women’s Health 5:233

120.

Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22(1):6–17PubMed